All In Biotech

Drug Trial Radar · NCT06475742

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

A Phase 3, Multicenter, Open-label, Single-arm, Extension Study to Evaluate the Long-term Safety and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

680

Planned (sponsor's estimate)

Start

Jul 30, 2024

Primary completion

Sep 2032

Study completion Sep 2032

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Jun 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe symptoms of systemic lupus erythematosus. The main questions it aims to answer are: * Whether cenerimod causes any adverse effects ('side effects') when given on top of drugs already being given for systemic lupus erythematosus. * How well cenerimod works to reduce symptoms of systemic lupus erythematosus when taken for up to 5 years. Participants taking part in this study will have already taken part in another study, where they received either cenerimod or placebo (look-alike substance containing no active drug) for 1 year. In this clinical study approximately 680 participants will receive cenerimod (on top of drugs already being given for systemic lupus erythematosus) for up to 5 years.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • CenerimodDrug

    Film-coated tablets at a dose of 4 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse eventsTime frame: Day 1 (post dose) to a maximum of 5.5 years
  2. Serious adverse eventsTime frame: Day 1 (post dose) to a maximum of 5.5 years
  3. Adverse events of special interestTime frame: Day 1 (post dose) to a maximum of 5.5 years

Locations

122 sites in 26 countries. Site status is shown where the registry gives one.

  • University of Colorado Denver

    Aurora, Colorado

  • Clinical Research of West Florida, Inc.

    Clearwater, Florida

  • Omega Research MetroWest, LLC

    DeBary, Florida

  • SouthCoast Research Center, Inc.

    Miami, Florida

  • Allied Biomedical Research Institute

    Miami, Florida

  • D&H National Research Centers INC

    Miami, Florida

  • Professional research Center INC

    Miami, Florida

  • San Marcus Res Clin Inc.

    Miami Lakes, Florida

  • Accurate Clinical Research Inc. - Lake Charles

    Lake Charles, Louisiana

  • RB Wellness Clinic

    Las Vegas, Nevada

  • Accurate Clinical Research Inc - (Najam)

    Baytown, Texas

  • Novel Research LLC

    Bellaire, Texas

  • Accurate Clinical Research Inc.

    Houston, Texas

  • Sun Research

    San Antonio, Texas

  • Aprillus Asistencia e Investigacion

    Buenos Aires, Argentina

  • Centro Médico Arsema

    Buenos Aires, Argentina

  • Fundación Respirar

    Buenos Aires, Argentina

  • IR Medical Center S.A.

    Mendoza, Argentina

  • Instituto Medico CER

    Quilmes, Argentina

  • Instituto CAICI SRL

    Rosario, Argentina

  • Centro de investigaciones medicas Tucuman

    San Miguel de Tucumán, Argentina

  • ICT (Investigaciones Clínicas Tucumán)

    San Miguel de Tucumán, Argentina

  • LMK Servicos Medico S/S

    Porto Alegre, Brazil

  • SER - Serviços Especializados em Reumatologia da Bahia

    Salvador, Brazil

  • Outpatient Clinic for Specialized Outpatient Medical Care - Medical Center Kyuchuk Parizh Ltd.

    Plovdiv, Bulgaria

  • DCC Equita EOOD

    Varna, Bulgaria

  • Enroll SpA

    Providencia, Chile

  • Biomedica Research Group

    Providencia, Chile

  • Sociedad Médica del Aparato Locomotor S. A.

    Providencia, Chile

  • Centro de Especialidades Medicas Vanguardia

    Temuco, Chile

  • Clinical Research Chile SpA

    Valdivia, Chile

  • Hospital San José de Victoria

    Victoria, Chile

  • Clínica de la costa S.A.S.

    Barranquilla, Colombia

  • IDEARG (Instituto de Enfermedades Autoinmunes Renato Guzmán)

    Bogotá, Colombia

  • Servimed S.A.S

    Bucaramanga, Colombia

  • Centro de Estudios de Reumatología y Dermatología

    Cali, Colombia

  • Preventive Care SAS

    Chía, Colombia

  • Hospital Pablo Tobon Uribe

    Medellín, Colombia

  • Healthy Medical Center SAS

    Zipaquirá, Colombia

  • iMedica s.r.o.

    Brno, Czechia

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.